Engineering human tissue implants

What is the Challenge?

Millions of patients around the world suffer due to severely diseased or lost organs or tissues, for which there are no available transplants or treatment options. Solutions based on artificial implants come with several challenges for patients and are often inadequate and short lasting, so the need for a paradigm shift towards biological solutions is more urgent than ever. What if we could use the body’s own cells to restore, maintain, or improve damaged tissues or organs?

What is the Solution?

Biotech company ClexBio is creating an entirely new type of bioengineered human tissue implants that can integrate with the human body, providing a potential cure for highly prevalent diseases that cannot be adequately addressed with artificial implants. Prime focus for the ambitious ClexBio team is to start by solving Chronic Venous Insufficiency, a common condition that affects 5-10 percent of adults globally, where insufficient blood flow in the veins, combined with damaged vein valves in severe cases, lead to “never-healing” wounds in the legs. Today there are virtually no treatment options available for these patients, they are sent home with compression stockings which have little to no effect if the disease progresses.

ClexBio owns the patent for a highly innovative method for creating biocompatible hydrogels as well as the technology to grow large tissues from healthy human cells in complex geometric shapes. It offers a radically different approach that enables scalable manufacturing of biocompatible human tissue grafts that are available off-the-shelf and, after transplantation, will be repopulated by the patient's own cells – rebuilding & regenerating damaged tissues in the patient's body. The proprietary CLEX™and VivoSet™ technologies are the result of many years of research and development within tissue engineering at some of the leading universities in Europe and the US.

Going forward, ClexBio is also looking to enter into co-development partnerships to apply its products in other areas of high unmet need, such as arterial and neural defects.